The European Medicines Agency (EMA) recommended the first drug for treating coronavirus infection
This was reported on the website of the agency.
The EMA Human Medicines Committee has recommended that remdesivir (commercial name Veklury) provide conditional commercial approval for the treatment of COVID-19 in adults and adolescents (12 years old).
The corresponding recommendation was issued on the basis of research conducted by a special procedure for public health emergencies since April 30.
In these studies, one patient was given the indicated drug for 10 days, and a placebo to the other. The study involved more than 1000 patients hospitalized with COVID-19.
“In general, the study found that patients taking remdesivir recovered after about 11 days, compared to 15 days in patients taking placebo. This effect was not observed in patients with mild to moderate illness: the time to recovery was 5 days for both the remdesivir group and the placebo group.
For patients with severe illness, which accounted for approximately 90% of the subjects, the time to recovery was 12 days in the remdesivir group and 18 days in the placebo group, ”the EMA noted.
It is also reported that for severe patients who started taking the drug when they were already connected to an artificial lung ventilation device or ECMO (extracorporeal membrane oxygenation), the drug did not help.
The manufacturer of the drug must provide the Agency with mortality data among patients taking the drug by August 2020. The final results of the study of the drug should be submitted before December 2020.